statnews.com·Apr 29, 2026
Pfizer and BridgeBio secured a patent win, while the FDA announced a new initiative to review clinical trial data in real time to expedite drug market entry. Additionally, Italian pharma company Chiesi is acquiring KalVista Therapeutics for $1.9 billion to enhance its rare disease portfolio.
The most valuable insight for a professional in healthtech and biotech is the FDA's announcement to start reviewing trial data in real time, beginning with oncology studies by AstraZeneca and Amgen. This significant shift could accelerate drug approval processes, offering strategic opportunities for faster market entry and innovation in drug development, particularly in oncology.